PP
PFE icon

Paladin Partners’s Pfizer PFE Stock Holding History

Paladin Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.28K Hold
80
– – ﹤0.01% 175
2026
Q2 		$1.93K Hold
80
– – ﹤0.01% 187
2026
Q1 		$2.25K Hold
80
– – ﹤0.01% 180
2025
Q4 		$1.99K Buy
+80
New +$2.02K ﹤0.01% 189

Other funds holding PFE

RT
Rockland Trust Hanover, Massachusetts $2.61B AUM 14.26% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
PNC
Park National Corp Newark, Ohio $3.69B AUM 18.32% 1-Year Est. Return
FFBTD
First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return
DS
Dudley & Shanley Palm Beach, Florida $629M AUM 7.61% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
ISB
Iowa State Bank Urbandale, Iowa $592M AUM 21.15% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
HWA
Heartwood Wealth Advisors Richmond, Virginia $1.27B AUM 11.08% 1-Year Est. Return

Paladin Partners's PFE Position: Q3 2026 in Review

Paladin Partners held its Pfizer (PFE) position steady in Q3 2026 at 80 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #175.

Paladin Partners first reported a position in PFE in Q4 2025 and has held it in 4 quarters since. 43 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Paladin Partners held 80 shares of Pfizer worth $2.28K as of Q3 2026.
  • Paladin Partners left its Pfizer share count unchanged in Q3 2026.
  • Pfizer made up ﹤0.01% of Paladin Partners's portfolio in Q3 2026, its #175 holding.
  • Paladin Partners first reported a position in Pfizer in Q4 2025 and has held it in 4 quarters since.
  • 43 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.